Cargando…

Progress of MRI Radiomics in Hepatocellular Carcinoma

BACKGROUND: Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world and the third leading cause of cancer-related death. Although the diagnostic scheme of HCC is currently undergoing refinement, the prognosis of HCC is still not satisfactory. In addition to certain factors, such...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Xue-Qin, Tao, Yun-Yun, Wu, Yao–Kun, Liu, Ning, Yu, Xi, Wang, Ran, Zheng, Jing, Liu, Nian, Huang, Xiao-Hua, Li, Jing-Dong, Yang, Gang, Wei, Xiao-Qin, Yang, Lin, Zhang, Xiao-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488263/
https://www.ncbi.nlm.nih.gov/pubmed/34616673
http://dx.doi.org/10.3389/fonc.2021.698373
_version_ 1784578124584845312
author Gong, Xue-Qin
Tao, Yun-Yun
Wu, Yao–Kun
Liu, Ning
Yu, Xi
Wang, Ran
Zheng, Jing
Liu, Nian
Huang, Xiao-Hua
Li, Jing-Dong
Yang, Gang
Wei, Xiao-Qin
Yang, Lin
Zhang, Xiao-Ming
author_facet Gong, Xue-Qin
Tao, Yun-Yun
Wu, Yao–Kun
Liu, Ning
Yu, Xi
Wang, Ran
Zheng, Jing
Liu, Nian
Huang, Xiao-Hua
Li, Jing-Dong
Yang, Gang
Wei, Xiao-Qin
Yang, Lin
Zhang, Xiao-Ming
author_sort Gong, Xue-Qin
collection PubMed
description BACKGROUND: Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world and the third leading cause of cancer-related death. Although the diagnostic scheme of HCC is currently undergoing refinement, the prognosis of HCC is still not satisfactory. In addition to certain factors, such as tumor size and number and vascular invasion displayed on traditional imaging, some histopathological features and gene expression parameters are also important for the prognosis of HCC patients. However, most parameters are based on postoperative pathological examinations, which cannot help with preoperative decision-making. As a new field, radiomics extracts high-throughput imaging data from different types of images to build models and predict clinical outcomes noninvasively before surgery, rendering it a powerful aid for making personalized treatment decisions preoperatively. OBJECTIVE: This study reviewed the workflow of radiomics and the research progress on magnetic resonance imaging (MRI) radiomics in the diagnosis and treatment of HCC. METHODS: A literature review was conducted by searching PubMed for search of relevant peer-reviewed articles published from May 2017 to June 2021.The search keywords included HCC, MRI, radiomics, deep learning, artificial intelligence, machine learning, neural network, texture analysis, diagnosis, histopathology, microvascular invasion, surgical resection, radiofrequency, recurrence, relapse, transarterial chemoembolization, targeted therapy, immunotherapy, therapeutic response, and prognosis. RESULTS: Radiomics features on MRI can be used as biomarkers to determine the differential diagnosis, histological grade, microvascular invasion status, gene expression status, local and systemic therapeutic responses, and prognosis of HCC patients. CONCLUSION: Radiomics is a promising new imaging method. MRI radiomics has high application value in the diagnosis and treatment of HCC.
format Online
Article
Text
id pubmed-8488263
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84882632021-10-05 Progress of MRI Radiomics in Hepatocellular Carcinoma Gong, Xue-Qin Tao, Yun-Yun Wu, Yao–Kun Liu, Ning Yu, Xi Wang, Ran Zheng, Jing Liu, Nian Huang, Xiao-Hua Li, Jing-Dong Yang, Gang Wei, Xiao-Qin Yang, Lin Zhang, Xiao-Ming Front Oncol Oncology BACKGROUND: Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world and the third leading cause of cancer-related death. Although the diagnostic scheme of HCC is currently undergoing refinement, the prognosis of HCC is still not satisfactory. In addition to certain factors, such as tumor size and number and vascular invasion displayed on traditional imaging, some histopathological features and gene expression parameters are also important for the prognosis of HCC patients. However, most parameters are based on postoperative pathological examinations, which cannot help with preoperative decision-making. As a new field, radiomics extracts high-throughput imaging data from different types of images to build models and predict clinical outcomes noninvasively before surgery, rendering it a powerful aid for making personalized treatment decisions preoperatively. OBJECTIVE: This study reviewed the workflow of radiomics and the research progress on magnetic resonance imaging (MRI) radiomics in the diagnosis and treatment of HCC. METHODS: A literature review was conducted by searching PubMed for search of relevant peer-reviewed articles published from May 2017 to June 2021.The search keywords included HCC, MRI, radiomics, deep learning, artificial intelligence, machine learning, neural network, texture analysis, diagnosis, histopathology, microvascular invasion, surgical resection, radiofrequency, recurrence, relapse, transarterial chemoembolization, targeted therapy, immunotherapy, therapeutic response, and prognosis. RESULTS: Radiomics features on MRI can be used as biomarkers to determine the differential diagnosis, histological grade, microvascular invasion status, gene expression status, local and systemic therapeutic responses, and prognosis of HCC patients. CONCLUSION: Radiomics is a promising new imaging method. MRI radiomics has high application value in the diagnosis and treatment of HCC. Frontiers Media S.A. 2021-09-20 /pmc/articles/PMC8488263/ /pubmed/34616673 http://dx.doi.org/10.3389/fonc.2021.698373 Text en Copyright © 2021 Gong, Tao, Wu, Liu, Yu, Wang, Zheng, Liu, Huang, Li, Yang, Wei, Yang and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Gong, Xue-Qin
Tao, Yun-Yun
Wu, Yao–Kun
Liu, Ning
Yu, Xi
Wang, Ran
Zheng, Jing
Liu, Nian
Huang, Xiao-Hua
Li, Jing-Dong
Yang, Gang
Wei, Xiao-Qin
Yang, Lin
Zhang, Xiao-Ming
Progress of MRI Radiomics in Hepatocellular Carcinoma
title Progress of MRI Radiomics in Hepatocellular Carcinoma
title_full Progress of MRI Radiomics in Hepatocellular Carcinoma
title_fullStr Progress of MRI Radiomics in Hepatocellular Carcinoma
title_full_unstemmed Progress of MRI Radiomics in Hepatocellular Carcinoma
title_short Progress of MRI Radiomics in Hepatocellular Carcinoma
title_sort progress of mri radiomics in hepatocellular carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488263/
https://www.ncbi.nlm.nih.gov/pubmed/34616673
http://dx.doi.org/10.3389/fonc.2021.698373
work_keys_str_mv AT gongxueqin progressofmriradiomicsinhepatocellularcarcinoma
AT taoyunyun progressofmriradiomicsinhepatocellularcarcinoma
AT wuyaokun progressofmriradiomicsinhepatocellularcarcinoma
AT liuning progressofmriradiomicsinhepatocellularcarcinoma
AT yuxi progressofmriradiomicsinhepatocellularcarcinoma
AT wangran progressofmriradiomicsinhepatocellularcarcinoma
AT zhengjing progressofmriradiomicsinhepatocellularcarcinoma
AT liunian progressofmriradiomicsinhepatocellularcarcinoma
AT huangxiaohua progressofmriradiomicsinhepatocellularcarcinoma
AT lijingdong progressofmriradiomicsinhepatocellularcarcinoma
AT yanggang progressofmriradiomicsinhepatocellularcarcinoma
AT weixiaoqin progressofmriradiomicsinhepatocellularcarcinoma
AT yanglin progressofmriradiomicsinhepatocellularcarcinoma
AT zhangxiaoming progressofmriradiomicsinhepatocellularcarcinoma